By 2033, the worldwide biodefense market is projected to have grown from its 2023 valuation of US$ 16.31 billion to US$ 32.99 billion. It is anticipated that this market would expand at a CAGR of 7.3% during the analysed period. With the increasing need for medications, vaccines, and medical gadgets, businesses will have more chances to grow and penetrate new markets.
Countries must maintain a constant supply of vaccines and biothreat detection technology to ensure their citizens’ safety. Initiatives like these can accelerate the growth of the biodefense industry.
A combination of government initiatives, increased government attention, and funding for biodefense strategies help fuel the biodefense market. As a result, these agents can cause social and economic turmoil. To protect warfighters from novel biological agents, the Department of Defense is modernizing its medical countermeasures approach.
Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16664
The scope of the biodefense market may be further expanded by increasing private investment. This is due to the occurrence of different viruses such as the flu, the Ebola virus, and the Zika virus. Says a lead analyst at Future Market Insights.
Key Takeaways:
•The biodefense market is anticipated to expand at a CAGR of 7.3% over the forecast period.
- According to estimates, the biodefense market in North America is going to remain strong and account for 79% of the market share throughout the length of the forecast period.
- China is expected to secure a high rate of 8.8% due to surges in research and development.
- The anthrax segment held a significant market share of 28.1% in 2023.
Competitive Landscape:
Several prominent companies dominate this market, including Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc. and others.
Many players are collaborating with governments in emerging and economically advantageous regions to gain bulk orders and boost sales. Key manufacturers are strengthening their presence in the market and staying ahead of the competition through expansion, new product launches, and approvals.
Recent Developments:
•A biodefense vaccine candidate developed by Appili Therapeutics Inc., ATI-1701, is expected to prevent Francisella tularensis infection by the end of February 2022 for over US$ 10 million. This funding may boost the company’s market share and growth in the biodefense market.
- In an announcement, Emergent BioSolutions Inc. announced that its Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) had been approved by the United States Food and Drug Administration (FDA).
- Ichor Medical Systems, Inc., a privately held company, announced in March 2019 that it had entered into a collaboration and research license agreement with AstraZeneca to develop plasmid DNA constructs (recombinant monoclonal antibodies) for clinical testing. The terms of the agreement also include development milestone payments in addition to upfront and annual payments for Ichor.
- In August 2018, CEPI (Coalition for Epidemic Preparedness Innovations) announced a collaboration with Profectus BioSciences, Inc. A vaccine against the Lassa virus was manufactured by Emergent BioSolutions Inc. By collaborating, these companies were able to expand their product portfolios and increase sales.
Biodefense Market Segmentation by Category
By Product:
•Anthrax
•Smallpox
•Botulism
•Radiation/Nuclear
By Region Outlook:
•North America
•Latin America
•Europe
•The Middle East and Africa
•East Asia
